Skip to content

CBD: all studies

Page 5 of 38: studies 41 to 50 of 375, newest first. Back to the CBD overview

Research

Cannabidiol-Derived Cannabinoids: The Unregulated Designer Drug Market Following the 2018 Farm Bill

Medical Cannabis and Cannabinoids February 13, 2024 Charles N. Zawatsky, Sara Mills-Huffnagle, Corinne M. Augusto et al.

Background: In this review, we summarize current scientific knowledge on psychoactive cannabinoids synthesized from cannabidiol (CBD) and sold in the semi-legal market established in response to the passage of the US Agriculture Improvement Act of 2018, commonly known as the 2018 Farm Bill. The discussion focuses on recent developments that suggest this unregulated market may be fertile ground...

Cannabidiol does not attenuate acute delta-9-tetrahydrocannabinol-induced attentional bias in healthy volunteers: A randomised, double-blind, cross-over study.

Addiction February 2024 Dominic Oliver, Amir Englund, Edward Chesney et al.

To test how attentional bias and explicit liking are influenced by delta-9-tetrahydrocannabinol (THC) and whether these effects are moderated by cannabidiol (CBD). Double-blind, randomised, within-subjects cross-over study. NIHR Wellcome Trust Clinical Research Facility at King's College Hospital, London, United Kingdom. Forty-six infrequent cannabis users (cannabis use <1 per week). Across...

Cannabidiol, but Not Δ9-Tetrahydrocannabinol, Has Strain- and Genotype-Specific Effects in Models of Psychosis

Cannabis and Cannabinoid Research February 1, 2024 Catharine A. Mielnik, Chun Kit Li, Amy J. Ramsey et al.

Introduction: Cannabis use has been associated with an increased incidence of psychiatric disorders, yet the underlying neurobiological processes mediating these associations are poorly understood. Whereas exposure to Δ9-tetrahydrocannabinol (THC) has been associated with the development or exacerbation of psychosis, treatment with cannabidiol (CBD) has been associated with amelioration of...

Cannabinoid Exposure and Subjective Effects of THC and CBD in Edible Cannabis Products.

Cannabis and Cannabinoid Research February 1, 2024 Laurel P Gibson, Raeghan L. Mueller, Evan A Winiger et al.

Background: The popularity of edible cannabis products continues to grow in states with legal cannabis access, but few studies have investigated the acute effects of these commercially available products. The present study sought to explore the effects of three commercially available edible products with different levels of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD). Methods: A...

Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study

Cannabis and Cannabinoid Research January 22, 2024 L. Bidwell, Renée Martin-Willett, Carillon J. Skrzynski et al.

Objective: Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) have varying pharmacological actions with differential effects on acute and extended affective states, incuding anxiety. We aimed to study these effects on anxiety in legal market forms of cannabis. Method: This study makes use of a nonequivalent control group quasiexperimental design. Forty-two participants with anxiety symptions...

Feasibility of a cannabidiol-dominant cannabis-based medicinal product for the treatment of long COVID symptoms: A single-arm open-label feasibility trial.

British Journal of Clinical Pharmacology January 17, 2024 Hannah Thurgur, Michael T. Lynskey, Anne Katrin Schlag et al. 7 citations

Aims: To conduct a single-arm open-label feasibility trial of the safety and tolerability of a full-spectrum cannabidiol (CBD)-dominant cannabis-based medicinal product for treating the symptoms of long COVID. Methods: The treatment phase ran for a total of 21 weeks, followed by ~3 weeks without the study drug. Participants received up to 3 mL of MediCabilis 5% CBD Oil (50 mg CBD/mL, <2 mg...

DOI: 10.1111/bcp.15988 (opens in new tab) Long covid treatment Post-covid condition therapy Chronic covid management Long-haul covid remedy +15

Perspectives toward cannabidiol (CBD) among youth in Early Psychosis Intervention programs: A qualitative study.

Early Intervention in Psychiatry January 2024 Amar Ghelani

Cannabis is used by one third of youth in Early Psychosis Intervention (EPI) programs and high dose consumption of the primary constituent Δ-9 tetrahydrocannabinol (THC) is associated with higher risk for relapse in this group. Cannabidiol (CBD) is a secondary cannabis constituent that may have antipsychotic properties, though its health risks are only beginning to be understood. Little is...

Cannabidiol or ketamine for preventing the impact of adolescent early drug initiation on voluntary ethanol consumption in adulthood.

Frontiers in Pharmacology 2024 Carles Colom-Rocha, Cristian Bis-Humbert, M Julia García-Fuster 3 citations

Few studies have previously evaluated the long-term impact of initiating the combined use of alcohol and cocaine early-in-life during adolescence. Our preclinical study characterized changes in affective-like behavior and/or voluntary ethanol consumption emerging later on in adulthood induced by a prior adolescent drug exposure, as well as tested therapeutical interventions (i.e., cannabidiol...

Effects of the Acute and Chronic Administration of Cannabidiol on Cognition in Humans and Animals: A Systematic Review.

Cannabis and Cannabinoid Research December 2023 Ana Julia de Lima Bomfim, Stefany Mirrelle Fávero Zuze, Daiene de Morais Fabrício et al.

Introduction: The effects of cannabidiol (CBD) on cognition has been investigated in recent years to determine the therapeutic potential of this cannabinoid for a broad gamut of medical conditions, including neuropsychiatric disorders. The aim of the present study was to perform a systematic review of studies that analyzed the effects of the acute and chronic administration of CBD on cognition...

Baseline affective symptomatology moderates acute subjective effects of high potency THC and CBD cannabis concentrates.

Experimental and Clinical Psychopharmacology December 2023 Renée Martin-Willett, Carillon J. Skrzynski, Hollis C Karoly et al.

Highly potent cannabis concentrates are widely available and associated with affective disturbance and cannabis use disorder. Little is known about the effects of concentrated Δ9-tetrahydrocannabinol (THC) and cannabidiol (CBD) and their relationship to long-term affect. We explored how baseline affective symptoms (anxiety and depression) relate to acute (i.e., immediate or short-term)...